tetano
Editor, Senior Moderator
BMC Infect Dis
. 2021 Aug 13;21(1):811.
doi: 10.1186/s12879-021-06532-7.
Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report
Marco Meazza Prina[SUP] 1 [/SUP], Francesca Martini[SUP] 2 [/SUP], Federico Bracchi[SUP] 1 [/SUP], Daniela Di Mauro[SUP] 1 [/SUP], Anna Fargnoli[SUP] 1 [/SUP], Marco Motta[SUP] 1 [/SUP], Cristina Giussani[SUP] 1 [/SUP], Giovanni Gobbin[SUP] 1 [/SUP], Monica Taverna[SUP] 1 [/SUP], Andrea D'Alessio[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Hemophagocytic syndrome (HPS) is a severe hyperinflammatory disease, whose diagnosis is based on the HLH-2004 criteria. In secondary forms of HLH (sHLH), the primary goal is treating the triggering factors such as COVID-19 (Coronavirus disease 2019). The link between the cytokine storm related to COVID-19 and development of sHLH has already been reported since the onset of pandemic, but little is known about clinical manifestations of HLH which develop after the patient's recovery from mild symptomatic or asymptomatic Sars-CoV-2 infection.
Case presentation: We describe the case of a woman diagnosed with sHLH related to previous Sars-CoV-2 infection and successfully treated with steroids, colchicine, etoposide and ruxolitinib.
Conclusions: Our report suggests that HLH-like syndrome might be secondary to Sars-CoV-2 infection, even if the patient utterly recovered from the mildly symptomatic viral infection. In addition, we underline the treatment with low dose ruxolitinib plus etoposide as a potential choice for Sars-CoV-2 infection related HLH.
Keywords: COVID-19; Case report; Hemophagocytic syndrome; Polyserositis.
. 2021 Aug 13;21(1):811.
doi: 10.1186/s12879-021-06532-7.
Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report
Marco Meazza Prina[SUP] 1 [/SUP], Francesca Martini[SUP] 2 [/SUP], Federico Bracchi[SUP] 1 [/SUP], Daniela Di Mauro[SUP] 1 [/SUP], Anna Fargnoli[SUP] 1 [/SUP], Marco Motta[SUP] 1 [/SUP], Cristina Giussani[SUP] 1 [/SUP], Giovanni Gobbin[SUP] 1 [/SUP], Monica Taverna[SUP] 1 [/SUP], Andrea D'Alessio[SUP] 1 [/SUP]
Affiliations
- PMID: 34388982
- DOI: 10.1186/s12879-021-06532-7
Abstract
Background: Hemophagocytic syndrome (HPS) is a severe hyperinflammatory disease, whose diagnosis is based on the HLH-2004 criteria. In secondary forms of HLH (sHLH), the primary goal is treating the triggering factors such as COVID-19 (Coronavirus disease 2019). The link between the cytokine storm related to COVID-19 and development of sHLH has already been reported since the onset of pandemic, but little is known about clinical manifestations of HLH which develop after the patient's recovery from mild symptomatic or asymptomatic Sars-CoV-2 infection.
Case presentation: We describe the case of a woman diagnosed with sHLH related to previous Sars-CoV-2 infection and successfully treated with steroids, colchicine, etoposide and ruxolitinib.
Conclusions: Our report suggests that HLH-like syndrome might be secondary to Sars-CoV-2 infection, even if the patient utterly recovered from the mildly symptomatic viral infection. In addition, we underline the treatment with low dose ruxolitinib plus etoposide as a potential choice for Sars-CoV-2 infection related HLH.
Keywords: COVID-19; Case report; Hemophagocytic syndrome; Polyserositis.